A real life cohort of mepolizumab treatment in severe eosinophilic asthma

Laorden, D.; Hernández, I.; Domínguez-Ortega, J.; Romero, D.; Álvarez-Sala, R.; Quirce, S.

doi:10.23822/eurannaci.1764-1489.289

Cited by 2 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 Eosinophil cationic protein (ECP), also known as RNase A family 3 (RNASE3), has been widely described and standardized as a marker of tissue eosinophilia and eosinophil activation. 9 The biological properties and clinical role of ECP have been demonstrated. Jin reported that NPs patients had higher concentrations of ECP in nasal secretions than healthy subjects.…”

Section: Introductionmentioning

confidence: 99%

Up-regulation of systemic and local BDNF in non-allergic Nasal Polyps in China

Zhou,

Zhang,

Yuzhu Wan

et al. 2024

Pak J Med Sci

View full text Add to dashboard Cite

Objective: Although the role of brain-derived neurotrophic factor (BDNF) in allergic rhinitis and/or nasal polyps (NPs) development has been studied, the contribution of BDNF in non-allergic NPs has not been evaluated yet. This study was to investigate the possible role of BDNF in non-allergic NPs pathogenesis. Methods: The study was carried out at The Second Hospital of Shandong University from December 2020 to November 2021. The non-allergic NPs patients (n=26) and the control group (n=22) were included. Lund-Mackay CT scores, nasal endoscopy scores, and pulmonary function testing were evaluated before surgery. Tissue and serum levels of BDNF, eosinophil cationic protein (ECP), and cytokeratins 5 (CK5) were assessed between different groups. Result: The BDNF level in serum and tissue, CK5 count, and eosinophil infiltration in tissue were higher in non-allergic NPs. The eosinophils infiltration, ECP mRNA expression level, as well as BDNF mRNA level were increased in the BDNFhigh subgroup compared with BDNFlow subgroup. Significantly negative correlations between BDNF count and the situation of airway obstruction were found in non-allergic NPs. Conclusion: BDNF may have both local and systemic effects in non-allergic NPs pathogenesis. BDNF may be a possible therapeutic target or an indicator for eosinophilic NPs management. doi: https://doi.org/10.12669/pjms.40.5.7907 How to cite this: Zhou X, Zhang Q, Wan Y, Shi L. Up-regulation of systemic and local BDNF in non-allergic Nasal Polyps in China. Pak J Med Sci. 2024;40(5):---------. doi: https://doi.org/10.12669/pjms.40.5.7907 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Introductionmentioning

confidence: 99%

Up-regulation of systemic and local BDNF in non-allergic Nasal Polyps in China

Zhou,

Zhang,

Yuzhu Wan

et al. 2024

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…The serum levels of ECP have been linked to the degree of eosinophilic inflammation, suggesting that it could be an indirect marker of eosinophilic activity [ 15 ]. The levels of eosinophil cationic protein (ECP) were also deemed to be a reliable prognostic indicator for the recurrence of nasal polyps following surgical intervention.…”

Section: Introductionmentioning

confidence: 99%

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab

Ledda,

Costanzo,

Sambugaro

et al. 2023

Life

View full text Add to dashboard Cite

Background: Asthma is a clinical syndrome characterized by recurrent episodes of airway obstruction, bronchial hyperresponsiveness and airway inflammation. Most patients with asthma present a “type 2” (TH2) inflammation. ILC2 and TH2 cells release cytokines IL4, IL-13 and IL-5. CRSwNP is a condition characterized by hyposmia or anosmia, nasal congestion, nasal discharge, and face pain or pressure that last for at least 12 weeks in a row without relief. Both asthma and CRSwNP are often characterized by a type 2 inflammation endotype and are often present in the same patient. Dupilumab is a fully human monoclonal antibody targeting the interleukin-4 receptor α (IL-4Rα) subunit, blocking IL4/IL-4Rα binding and IL13. It has been labelled for the treatment of moderate to severe asthma in patients from the age of 12 years with an eosinophilic phenotype, and it has demonstrated efficacy and acceptable safety. Our study aims to investigate the effects of dupilumab on type 2 inflammatory biomarkers, such as eosinophils and eosinophil cationic protein (ECP). ECP is an eosinophil-derived substance contained in granules that are released during inflammation and causes various biological effects, including tissue damage in asthmatic airways. Methods: ECP, Eosinophil counts (EOS), and total immunoglobulin E (IgE) levels were longitudinally measured using immunoassays in the serum of 21 patients affected by CRSwNP, of which 17 had asthma as a comorbidity, receiving 300 mg dupilumab every two weeks. Results: The EOS and ECP, after a first phase of significant increase due to the intrinsic characteristic of the block of IL-4 and IL-13, returned to the baseline 10 months after the initial administration of dupilumab. Fractional exhaled nitric oxide (FeNO) and serum total IgE decreased significantly after 9 months. Asthma Control Test (ACT) scores improved after dupilumab treatment. FEV1% and FEV1 absolute registered a significant improvement at 10 months. Conclusions: Patients who received 300 milligrams of dupilumab every two weeks first experienced a temporary increase in eosinophils (EOS) and eosinophil cationic protein (ECP), then exhibited a gradual decline in these variables with a subsequent return to the initial baseline levels. When compared to the baseline, we observed that the levels of IgE and FeNO decreased over time, while there was an increase in both FEV1 and FEV1%.

show abstract

A real life cohort of mepolizumab treatment in severe eosinophilic asthma

Cited by 2 publications

References 28 publications

Up-regulation of systemic and local BDNF in non-allergic Nasal Polyps in China

Up-regulation of systemic and local BDNF in non-allergic Nasal Polyps in China

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab

Contact Info

Product

Resources

About